NLS Pharmaceutics to Present at the Access to Giving Virtual Investor Conference on July 15th
STANS, SWITZERLAND / ACCESSWIRE / July 9, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) announced that CEO Alex Zwyer will present a corporate overview at the First Annual Access to Giving Virtual Investor Conference from July 13-15, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
STANS, SWITZERLAND / ACCESSWIRE / July 9, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) announced that CEO Alex Zwyer will present a corporate overview at the First Annual Access to Giving Virtual Investor Conference from July 13-15, 2021. The presentation is scheduled for July 15th at 9:00 am ET, followed by a Q&A session. NLS focuses on innovative therapies for rare central nervous system disorders, with its lead candidate, Quilience®, aimed at treating narcolepsy, receiving Orphan Drug Designations in the U.S. and Europe.
Details
News Market Reaction – NLSP
The recorded move for NLSP in the trading session of this news was +0.65%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
STANS, SWITZERLAND / ACCESSWIRE / July 9, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer, Chief Executive Officer and Co-Founder, is scheduled to present a corporate overview at the First Annual Access to Giving Virtual Investor Conference which will take place July 13-15, 2021.
Mr. Zwyer will deliver his corporate presentation on July 15th at 9:00am ET and investors can access the event here. A Question & Answer session will follow the presentation.
About NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system disorders. The Company's lead product candidate, Quilience® is a proprietary extended-release formulation of mazindol (mazindol ER), and is being developed for the treatment of narcolepsy. Mazindol is a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. NLS completed a phase 2 study in the U.S. evaluating Nolazol® (mazindol controlled-release) in adult subjects with ADHD. The study met all primary and secondary endpoints and was well-tolerated. Quilience has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy.
Corporate Contact
Alex Zwyer, CEO: +41 41 618 80 00
Investor Relations Contact
Cindy Rizzo: +1 908-229-7050
www.nlspharma.com
SOURCE: NLS Pharmaceutics AG
View source version on accesswire.com:
https://www.accesswire.com/654818/NLS-Pharmaceutics-to-Present-at-the-Access-to-Giving-Virtual-Investor-Conference-on-July-15th
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.